News

By Gabriel Francisco Leonardos

Pharmaceutical IP and competition law in Brazil: 2019

A Q&A guide to pharmaceutical IP and competition law in Brazil. The Q&A gives a high level overview of key issues including patents, trade marks, competition law, patent licensing, generic entry, abuse of dominance and parallel imports.
Access the full Q&A, published by Thomsom Reuters Practical Law, by clicking here.
Back

Last by Gabriel Francisco Leonardos

September 3, 2021

The Covid-19 pandemic triggered the issuance of new compulsory license rules for patents in Brazil

On Sept. 2nd, 2021, Law No 14,200 was enacted to amend the Brazilian Patent & Trademark Act (BPTA) in order to change The Covid-19 pandemic triggered the issuance of new compulsory license rules for patents in Brazil

Ler notícia

August 27, 2021

The Brazilian FDA will no longer examine pharmaceutical patent applications

Law No. 14,195, of August 26, 2021, improves the business environment in Brazil   The participation of the Brazilian agency called ANVISA The Brazilian FDA will no longer examine pharmaceutical patent applications

Ler notícia

June 24, 2021

Text of the Business Environment Bill is approved by the Chamber of Representatives, and it ends the prior approval for pharmaceutical patents, in addition to bringing relevant changes to trade names

Ler notícia